Kadir Burak Özer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kadir Burak Özer has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ezgi Cesur
Department of Thoracic Surgery, Koc Healthcare American Hospital, 34365 Istanbul, Türkiye
1 shared publication - Pınar Bulutay
Department of Pathology Koç University School of Medicine Istanbul Türkiye
1 shared publication - Pınar Fırat
Department of Pathology, School of Medicine, Koç University, Istanbul 34450, Turkey
1 shared publication - Serhan Tanju
Department of Thoracic Surgery, Koç University School of Medicine, 34010 Istanbul, Türkiye
1 shared publication - Suat Erus
Department of Thoracic Surgery, Koç University School of Medicine, 34010 Istanbul, Türkiye
1 shared publication - Özgür Güzey
Department of Thoracic Surgery, Koç University School of Medicine, 34010 Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4582
Lymphatic Invasion Acts as a ‘Hidden Risk Factor’: Four-Fold Increased Mortality Risk in Early-Stage (TNM Stage I, N0) Non-Small Cell Lung Cancer
Background/Objectives: Despite advances in the TNM staging system, prognostic heterogeneity persists in early-stage non-small cell lung cancer (NSCLC). Lymphatic invasion (LI) is a known marker of aggression, but its independent significance in the critical, low-risk Stage I, N0 subgroup—typically ineligible for adjuvant therapy—remains poorly defined. We hypothesized that LI acts as a powerful, yet hidden, risk factor in this highly favourable cohort. Methods: This retrospective cohort study included 988 consecutive patients who underwent curative anatomical resection for NSCLC. All patients underwent complete resection with pathologically confirmed negative surgical margins (R0 resection). Cases were staged according to the 9th Edition of the TNM Classification of Malignant Tumours (TNM-9) and grouped as LI-positive or LI-negative. A critical subgroup analysis focused on 347 truly low-risk patients (TNM Stage I, N0, no vascular or pleural invasion). Overall survival (OS) was evaluated using the Kaplan–Meier method and multivariable Cox proportional hazards models. Results: In the entire cohort (n = 988), LI was present in 40.9% of cases. LI positivity was an independent predictor of worse OS in multivariable analysis (HR: 1.520, 95% CI: 1.004–2.301, p = 0.048). In the low-risk subgroup (n = 347), the presence of LI resulted in a drastic survival divergence, with 5-year OS declining from 96.1% (LI-negative) to 83.8% (LI-positive). Multivariable analysis confirmed LI as an independent adverse prognostic factor in this subgroup (HR: 4.002, 95% CI: 1.567–10.221, p = 0.004). Conclusions: Lymphatic invasion is a robust, independent adverse prognostic factor in resected NSCLC. LI may identify a subset of early-stage N0 NSCLC patients who warrant closer postoperative surveillance and prospective evaluation for adjuvant treatment strategies. Validation in prospective cohorts is required before LI can be formally integrated into staging algorithms or treatment guidelines.
- 12 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4582
Open AccessLymphatic Invasion Acts as a ‘Hidden Risk Factor’: Four-Fold Increased Mortality Risk in Early-Stage (TNM Stage I, N0) Non-Small Cell Lung Cancer
Background/Objectives: Despite advances in the TNM staging system, prognostic heterogeneity persists in early-stage non-small cell lung cancer (NSCLC). Lymphatic invasion (LI) is a known marker of aggression, but its independent significance in the critical, low-risk Stage I, N0 subgroup—typically ineligible for adjuvant therapy—remains poorly defined. We hypothesized that LI acts as a powerful, yet hidden, risk factor in this highly favourable cohort. Methods: This retrospective cohort study included 988 consecutive patients who underwent curative anatomical resection for NSCLC. All patients underwent complete resection with pathologically confirmed negative surgical margins (R0 resection). Cases were staged according to the 9th Edition of the TNM Classification of Malignant Tumours (TNM-9) and grouped as LI-positive or LI-negative. A critical subgroup analysis focused on 347 truly low-risk patients (TNM Stage I, N0, no vascular or pleural invasion). Overall survival (OS) was evaluated using the Kaplan–Meier method and multivariable Cox proportional hazards models. Results: In the entire cohort (n = 988), LI was present in 40.9% of cases. LI positivity was an independent predictor of worse OS in multivariable analysis (HR: 1.520, 95% CI: 1.004–2.301, p = 0.048). In the low-risk subgroup (n = 347), the presence of LI resulted in a drastic survival divergence, with 5-year OS declining from 96.1% (LI-negative) to 83.8% (LI-positive). Multivariable analysis confirmed LI as an independent adverse prognostic factor in this subgroup (HR: 4.002, 95% CI: 1.567–10.221, p = 0.004). Conclusions: Lymphatic invasion is a robust, independent adverse prognostic factor in resected NSCLC. LI may identify a subset of early-stage N0 NSCLC patients who warrant closer postoperative surveillance and prospective evaluation for adjuvant treatment strategies. Validation in prospective cohorts is required before LI can be formally integrated into staging algorithms or treatment guidelines.